CAJ | 학술논문

目的应用参一胶囊联合放疗治疗Ⅲ、Ⅳ期非小细胞肺癌(NSCLC),观察其临床疗效及不良反应.方法 63例Ⅲ、Ⅳ期NSCLC患者按简单随机化方法分为2组,治疗组,35例,给予放疗+参一胶囊处理；对照组,28例,放疗+安慰剂处理.比较2组患者的疗效及不良反应.结果治疗组的近期疗效为57.14％,显著高于对照组(32.14％,x2=3.91,P＜0.05),治疗组的中位生存期为14.2个月,显著长于对照组(11.2个月,x2=2.07,P＜0.05),治疗组的1年生存率为62.86％,显著高于对照组( 39.29％,x2 =4.40,P＜0.05)；治疗组中各种常见的不良反应(除咳嗽、发热外)发生率,均低于对照组,但两组间差异无统计学意义.结论参一胶囊联合放疗是治疗晚期NSCLC的有效方法,具有一定的减毒增效作用.
목적 응용삼일효낭연합방료치료Ⅲ、Ⅳ기비소세포폐암(NSCLC),관찰기림상료효급불량반응.방법 63례Ⅲ、Ⅳ기NSCLC환자안간단수궤화방법분위2조,치료조,35례,급여방료+삼일효낭처리；대조조,28례,방료+안위제처리.비교2조환자적료효급불량반응.결과 치료조적근기료효위57.14％,현저고우대조조(32.14％,x2=3.91,P＜0.05),치료조적중위생존기위14.2개월,현저장우대조조(11.2개월,x2=2.07,P＜0.05),치료조적1년생존솔위62.86％,현저고우대조조( 39.29％,x2 =4.40,P＜0.05)；치료조중각충상견적불량반응(제해수、발열외)발생솔,균저우대조조,단량조간차이무통계학의의.결론 삼일효낭연합방료시치료만기NSCLC적유효방법,구유일정적감독증효작용.
Objective To study the efficacy and toxicity of gensenoside-Rg3 (Rg3) combined with radiotherapy on non-small cell lung cancer ( NSCLC ) at advanced stages (Ⅲ and Ⅴ ).Methods Sixty-three patients with stage Ⅲ or Ⅳ NSCLC were divided randomly into two groups:treatment group ( n =35 ) treated with Rg3 combined with radiotherapy and control group ( n =28 ) treated with radiotherapy alone.The efficacy and side effects were compared after the treatment.Results The response rate ( CR + PR) of the treatment group was 57.14％,significantly higher than that of the control group (32.14％,x2 =3.91,P ＜ 0.05).The median survival time of the treatment group was 14.2 months,significantly longer than that of the control group ( 11.2 months,x2 =2.07,P ＜ 0.05 ).The one-year survival rate of the treatment group was 62.86％,significantly higher than that of the control group (39.29％,x2 =4.40,P ＜0.05).The incidence rates of side effects of the treatment group were all lower than those of the control group,but there were not significant difference. Conclusions Gensenoside-Rg3 combined with radiotherapy is effective for advanced stage NSCLC,with attenuation and synergistic effects.